A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Clear Cell Renal Cell Carcinoma (ccRCC)

Interventions

DRUG

[68Ga]Ga-OncoCAIX

Single intravenous bolus administration.

Trial Locations (3)

RECRUITING

IRCCS Ospedale San Raffaele, Milan

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

NOT_YET_RECRUITING

ASST Papa Giovanni XXIII, Bergamo

All Listed Sponsors

lead

Philogen S.p.A.

INDUSTRY

NCT06840548 - A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer | Biotech Hunter | Biotech Hunter